Dobutamine versus milrinone after subarachnoid hemorrhage

Neurosurgery

Volumn 56, Issue 1, 2005, Pages 21-26

  Naidech, Andrew ^a,b   Du, Yunling ^a   Kreiter, Kurt T ^a   Parra, Augusta ^a   Fitzsimmons, Brian Fred ^a   Lavine, Sean D ^a   Connolly, E Sander ^a   Mayer, Stephan A ^a   Commichau, Christopher ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Congestive heart failure; Dobutamine; Milrinone; Subarachnoid hemorrhage

Indexed keywords

DOBUTAMINE; INOTROPIC AGENT; MILRINONE; VASOPRESSIN;

ADULT; ARTERY CATHETER; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; MALE; PRIORITY JOURNAL; STUNNED HEART MUSCLE; SUBARACHNOID HEMORRHAGE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-AGONISTS; ADULT; DOBUTAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MILRINONE; MYOCARDIAL STUNNING; PHOSPHODIESTERASE INHIBITORS; SUBARACHNOID HEMORRHAGE;

EID: 11144245595     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000144780.97392.D7     Document Type: Article

References (42)

1. Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S: Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: Report of seven cases. Neurosurgery 48:723-728, 2001.
2. Aranda JM Jr, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS Jr, Leach D, Lopez LM, Hill JA: Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: A prospective, randomized trial. Am Heart J 145:324-329, 2003.
3. Brott T, Adams HP, Olinger CP, Marier JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M: Measurements of acute cerebral infarction: A clinical examination scale. Stroke 20:864-870, 1989.
4. Bulsara KR, McGirt MJ, Liao L, Villavicencio AT, Borel C, Alexander MJ, Friedman AH: Use of the peak troponin value to differentiate myocardial infarction from reversible neurogenic left ventricular dysfunction associated with aneurysmal subarachnoid hemorrhage. J Neurosurg 98:524-528, 2003.
5. Deehan SC, Grant IS: Haemodynamic changes in neurogenic pulmonary oedema: Effect of dobutamine. Intensive Care Med 22:672-676, 1996.
6. DiDomenico RJ, Park HY, Southworth MR, Eyrich HM, Lewis RK, Finley JM, Schumock GT: Guidelines for acute decompensated heart failure treatment. Ann Pharmacother 38:649-660, 2004.
7. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084, 2000.
8. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 333:1025-1032, 1995.
9. Gupta D, Sharma BS, Gupta SK, Bapuraj R, Khosla VK: Postoperative hypertensive-hypervolaemic-haemodilution (Triple H) therapy in the treatment of vasospasm following aneurysmal subarachnoid haemorrhage. Neurol India 48:126-131, 2000.
10. Handlin LR, Kindred LH, Beauchamp GD, Vacek JL, Rowe SK: Reversible left ventricular dysfunction after subarachnoid hemorrhage. Am Heart J 126:235-240, 1993.
11. Hunt WE, Hess RM: Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 28:14-20, 1968.
12. Joseph M, Ziadi S, Nates J, Dannenbaum M, Malkoff M: Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: A study using xenon computed tomographic measurement of cerebral blood flow. Neurosurgery 53:1044-1051, 2003.
13. Khajavi K, Ayzman I, Shearer D, Jones SC, Levy JH, Prayson RA, Skibinski CI, Hahn JF, Chyatte D: Prevention of chronic cerebral vasospasm in dogs with milrinone. Neurosurgery 40:354-362, 1997.
14. Kieback AG, Iven H, Stolzenburg K, Baumann G: Saterinone, dobutamine, and sodium nitroprusside: Comparison of cardiovascular profiles in patients with congestive heart failure. J Cardiovasc Pharmacol 32:629-636, 1998.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE H: A severity of disease classification system. Crit Care Med 13:818-829, 1985.
16. Knudsen F, Jensen HP, Petersen PL: Neurogenic pulmonary edema: Treatment with dobutamine. Neurosurgery 29:269-270, 1991.
17. Kono T, Morita H, Kuroiwa T, Onaka H, Takatsuka H, Fujiwara A: Left ventricular wall motion abnormalities in patients with subarachnoid hemorrhage: Neurogenic stunned myocardium. J Am Coll Cardiol 24:636-639, 1994.
18. Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Stern Y, Connolly ES Jr, Mayer SA: Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke 33:200-208, 2002.
19. Kunimoto F, Isa Y, Ohki S, Tsukagoshi H, Yoshikawa D, Ishikawa S, Koyama H, Goto F: Comparison of the hemodynamic effects of amrinone in patients who required low-to-moderate-dose and high-dose catecholamines after cardiac valve replacement. Crit Care Med 27:2698-2702, 1999.
20. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 38:963-974, 1982.
21. Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, Wu YC, Klebanoff LM, Raps EC, Solomon RA: Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: A randomized controlled trial. Stroke 31:383-391, 2000.
22. Levy ML, Giannotta SL: Cardiac performance indices during hypervolemic therapy for cerebral vasospasm. J Neurosurg 75:27-31, 1991.
23. Levy ML, Rabb CH, Zelman V, Giannotta SL: Cardiac performance enhancement from dobutamine in patients refractory to hypervolemic therapy for cerebral vasospasm. J Neurosurg 79:494-499, 1993.
24. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR: Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 81:141-149, 2001.
25. Macmillan CS, Grant IS, Andrews PJ: Pulmonary and cardiac sequelae of subarachnoid haemorrhage: Time for active management? Intensive Care Med 28:1012-1023, 2002.
26. Mayer SA, Fink ME, Homma S, Sherman D, Lennihan L, Solomon RA, Klebanoff LM, Beckford A, Raps EC: Cardiac injury associated with neurogenic pulmonary edema following subarachnoid hemorrhage. Neurology 44:815-820,1994.
27. Minegishi A, Ishizaki T, Yoshida Y, Ahagon A, Shibata N, Kobayashi H: Plasma monoaminergic metabolites and catecholamines in subarachnoid hemorrhage: Clinical implications. Arch Neurol 44:423-428, 1987.
28. Monrad ES, Baim DS, Smith HS, Lanoue AS: Milrinone, dobutamine, and nitroprusside: Comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73:168-174, 1986.
29. O'Connor PJ, Welsh KR, Cross MH, Shah MV: Cardiovascular responses to pulmonary artery catheterization. Eur J Anaesthesiol 17:168-172, 2000.
30. Oropello JM, Weiner L, Benjamin E: Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage: Is it efficacious? No. Crit Care Clin 12:709-730, 1996.
31. Pinto RJ, Goyal V, Sharma S, Bhagwati SN: Transient myocardial dysfunction in a patient with subarachnoid haemorrhage. Int J Cardiol 46:289-291, 1994.
32. Polanczyk CA, Rohde LE, Goldman L, Cook EF, Thomas EJ, Marcantonio ER, Mangione CM, Lee TH: Right heart catheterization and cardiac complications in patients undergoing noncardiac surgery: An observational study. JAMA 286:309-314, 2001.
33. Pollick C, Cujec B, Parker S, Tator C: Left ventricular wall motion abnormalities in subarachnoid hemorrhage: An echocardiographic study. J Am Coll Cardiol 12:600-605, 1988.
34. Raymer K, Choi P: Concurrent subarachnoid haemorrhage and myocardial injury. Can J Anaesth 44:515-519, 1997.
35. Rosenwasser RH, Jallo JI, Getch CC, Liebman KE: Complications of Swan-Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Neurosurgery 37:872-875, 1995.
36. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, Laporta DP, Viner S, Passerini L, Devitt H, Kirby A, Jacka M: Pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 348:5-14, 2003.
37. Sato K, Masuda T, Izumi T: Subarachnoid hemorrhage and myocardial damage clinical and experimental studies. Jpn Heart J 40:683-701, 1999.
38. Schell AR, Shenoy MM, Friedman SA, Patel AR: Pulmonary edema associated with subarachnoid hemorrhage: Evidence for a cardiogenic origin. Arch Intern Med 147:591-592, 1987.
39. Solomon RA, McCormack BM, Lovitz RN, Swift DM, Hegemann MT: Elevation of brain norepinephrine concentration after experimental subarachnoid hemorrhage. Neurosurgery 19:363-366, 1986.
40. Teasdale G, Jennett B: Assessment of coma and impaired consciousness: A practical scale. Lancet 2:81-83, 1974.
41. Ullman JS, Bederson JB: Hypertensive, hypervolemic, hemodilutional therapy for aneurysmal subarachnoid hemorrhage: Is it efficacious? Yes. Crit Care Clin 12:697-707, 1996.
42. Yasu T, Owa M, Omura N, Katsuki T, Saito M: Transient ST elevation and left ventricular asynergy associated with normal coronary artery in aneurysmal subarachnoid hemorrhage. Chest 103:1274-1275, 1993.